Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases Uncategorized
University of Alberta Assigns Full Suite of Patents to 48Hour Discovery as Revenue Exceeds $5 Million Triggering Key Milestone Uncategorized
Research Chair recieves $8 million over the next eight years to continue his work at the University of Alberta Uncategorized
Syantra Announces Liquid Biopsy Platform Breakthrough with Expanded Intellectual Property Portfolio; Partnership with Limmi to Accelerate AI-Powered RNA-Based Early Cancer Detection Liquid Biopsy Program Uncategorized